L'intérêt à découvert pour Pacific Biosciences donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Pacific Biosciences. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Pacific Biosciences (NASDAQ:PACB) Stock, Rapport sur les intérêts à découvert

PACIFIC BIOSCIENCES OF CALIF

Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease
BOSTON, July 29, 2025 /PRNewswire/ --&nbsp;Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxia, a group of progressive, degenerative neurological disorders that affect movement or coordination.
The new service is a laboratory developed test that identifies sequences of DNA that repeat many times across a long stretch of the genome. Conventional sequencing technologies are adept at elucidating short DNA sequences but may fail to discern complex or large repeating sequences. Genetic causes of ataxia include expansions of repeating sequences in various genes, which go undetected in many conventional genetic sequencing panels. The new service will be used to confirm initial screening results delivered using polymerase chain reaction (PCR) testing. Healthcare providers may now order the test from Athena Diagnostics.
Under a collaboration agreement with PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), Quest developed and validated the new lab developed test using specialized technology based on PacBio's PureTarget method. Athena used the technology to develop and validate its ataxia test in Athena's advanced laboratory in Marlborough, Mass. Athena is also exploring options to develop and deploy a test based on PacBio technology to improve carrier screening.

News

PACB

Quest Diagnostics' Athena Diagnostics Announces New Laboratory Test Service Intended To Provide Insights Into Genetic Causes Of Ataxia

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease
BOSTON, July 29, 2025 /PRNewswire/ --&nbsp;Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxia, a group of progressive, degenerative neurological disorders that affect movement or coordination.
The new service is a laboratory developed test that identifies sequences of DNA that repeat many times across a long stretch of the genome. Conventional sequencing technologies are adept at elucidating short DNA sequences but may fail to discern complex or large repeating sequences. Genetic causes of ataxia include expansions of repeating sequences in various genes, which go undetected in many conventional genetic sequencing panels. The new service will be used to confirm initial screening results delivered using polymerase chain reaction (PCR) testing. Healthcare providers may now order the test from Athena Diagnostics.
Under a collaboration agreement with PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), Quest developed and validated the new lab developed test using specialized technology based on PacBio's PureTarget method. Athena used the technology to develop and validate its ataxia test in Athena's advanced laboratory in Marlborough, Mass. Athena is also exploring options to develop and deploy a test based on PacBio technology to improve carrier screening.
In a study available as a preprint, a PureTarget gene panel was found to identify a specific repeating gene pattern associated with Spinocerebellar ataxia type 10 that may be associated with age of disease onset, information that may help guide care decisions.

Biotech

General

Athena Diagnostics Launches New Genetic Test For Ataxia Using PacBio's PureTarget Sequencing Technology

<ul>
<li>Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing</li>
<li>Supports NGS platforms such as PacBio for applications including structural variants, HLA typing and repeat expansions</li>
<li>QIAGEN supporting fully integrated workflow from best-in-class sample preparation through to powerful bioinformatics for analysis and interpretation</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions.
This new offering strengthens QIAGEN's position as a provider of differentiated solutions for use on any next-generation sequencing (NGS) platforms spanning both short- and long-read technologies.
The new QIAGEN panels are optimized for use with native long-read platforms, including from PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), and designed to enable researchers to capture a broader spectrum of genomic variation. Applications include HLA typing, repeat expansion analysis, and the detection of structural variants – areas where short-read sequencing have been shown to have challenges.

QGEN

QIAGEN Launches QIAseq xHYB Long Read Panels, Suite Of Target Enrichment Solutions Designed To Unlock Long-Read Sequencing Of Genomically Complex Regions

Ratings for Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1.89, with a high estimate of $3.00 and a low estimate of $1.25. A negative shift in sentiment is evident as analysts have decreased the average price target by 14.09%. 
<img src="https://www.benzinga.com/files/images/story/2025/1750860056_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Pacific Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$1.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.25</td>
<td>$2.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$1.80</td>
<td>$1.80</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacific Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Pacific Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Pacific Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Pacific Biosciences</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>Unraveling the Financial Story of Pacific Biosciences</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Pacific Biosciences's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -4.27% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Pacific Biosciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1146.81%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Pacific Biosciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -142.44%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Pacific Biosciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -40.17%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 7.63, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Equal-Weight and lowers the price target from $2 to $1.5.

Price Target

Barclays Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $1.5

<h3>Gainers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock rose 15.2% to $0.71 during Friday's after-market session. The company's market cap stands at $115.5 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock increased by 10.45% to $3.91. The company's market cap stands at $756.9 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares rose 6.93% to $3.7. The company's market cap stands at $69.5 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) stock moved upwards by 6.62% to $0.77. The company's market cap stands at $59.9 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) stock rose 6.35% to $0.34. The company's market cap stands at $14.3 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares rose 5.93% to $0.19. The company's market cap stands at $24.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock declined by 10.4% to $0.02 during Friday's after-market session. The company's market cap stands at $7.3 million. </li>
<li>Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) shares fell 9.17% to $1.09. The market value of their outstanding shares is at $327.0 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares declined by 8.7% to $0.32. The company's market cap stands at $10.0 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares declined by 8.22% to $0.45. The market value of their outstanding shares is at $2.1 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) stock declined by 7.08% to $1.05. The company's market cap stands at $34.7 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock fell 7.07% to $6.05. The market value of their outstanding shares is at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APLM

BMGL

CLDI

ENTO

HCTI

HYPR

IRWD

JUNS

RLYB

SSII

12 Health Care Stocks Moving In Friday's After-Market Session

Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide
NEW YORK and MENLO PARK, Calif., June 2, 2025 /PRNewswire/ --&nbsp;Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), a leading provider of high-quality, highly accurate long read sequencing platforms,&nbsp;to launch the largest global whole genome sequencing initiative for ALS to date. By applying PacBio's HiFi sequencing to more than 6,000 genomes from people with ALS and healthy controls, the project aims to detect structural variants, repeat expansions, and other hard-to-detect genetic features that may underlie the disease. As part of the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439820-1&amp;h=3735549858&amp;u=https%3A%2F%2Fwww.targetals.org%2Fagri%2F&amp;a=ALS+Global+Research+Initiative+(AGRI)">ALS Global Research Initiative (AGRI)</a>, all data will be openly shared via the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439820-1&amp;h=2475819481&amp;u=https%3A%2F%2Fdataengine.targetals.org%2Fcollections&amp;a=Target+ALS+Data+Engine">Target ALS Data Engine</a>, removing barriers to access and enabling researchers around the world to uncover disease mechanisms and explore new pathways to treatment.

Target ALS Partners With PacBio To Launch Largest Global Whole Genome Sequencing Initiative For ALS To Date

PacBio Biosciences Of California Announces China Distributor To Expand Access To Its HiFi Long-Read Sequencing Technology In Clinical And Research Settings

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and lowers the price target from $2 to $1.25.

Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.25

Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $2.13, with a high estimate of $3.00 and a low estimate of $1.50. This current average has decreased by 27.05% from the previous average price target of $2.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1747317706_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Pacific Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$1.80</td>
<td>$1.80</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$2.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.50</td>
<td>$1.75</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pacific Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Pacific Biosciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Pacific Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Pacific Biosciences</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>Unraveling the Financial Story of Pacific Biosciences</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Pacific Biosciences faced challenges, resulting in a decline of approximately -4.27% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacific Biosciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1146.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Pacific Biosciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -142.44%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Pacific Biosciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -40.17%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pacific Biosciences's debt-to-equity ratio stands notably higher than the industry average, reaching 7.63. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Pacific Biosciences Stands With Analysts

Stephens &amp; Co. analyst Mason Carrico reiterates Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Overweight and maintains $1.8 price target.

Reiteration

Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $1.8 Price Target

PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the investigation found no improper employment practices and no material inaccuracies or omissions with respect to the cybersecurity disclosures in the Company's 2024 Form 10-K.

PacBio Independent Investigation Finds No Issues in Employment & Cybersecurity Matters

WIIM

Pacific Biosciences shares are trading lower. The company reported Q1 financial results.

Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.19) by 21.05 percent. This is a 42.31 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $37.15 million which beat the analyst consensus estimate of $34.81 million by 6.73 percent. This is a 4.27 percent decrease over sales of $38.81 million the same period last year.

Earnings

Earnings Beats

Pacific Biosciences Q1 Adj. EPS $(0.15) Beats $(0.19) Estimate, Sales $37.15M Beat $34.81M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

PacBio&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This marks the first initiative in Asia Pacific to explore the use of PacBio's HiFi sequencing technology at population scale - an effort designed to evaluate how comprehensive genomic data can support earlier, more accurate identification of rare and treatable conditions in newborns. The collaboration highlights Thailand's growing leadership in precision medicine and offers a potential model for countries seeking to modernize newborn screening with genome-wide approaches.

PacBio Announces Strategic Collaboration To Implement PacBio HiFi Whole Genome Sequencing As Part Of Newborn Screening Research Program

On Wednesday, Cathie Wood-led Ark Invest executed significant trades involving Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and Shopify Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>). 
The Palantir Trade
Ark Invest made a notable move by selling shares of Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) across ARK Next Generation Internet ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#BATS">ARKW</a>) and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>). The sale involved 19,005 shares in ARKW and 3,375 shares in ARKX. With Palantir&#8217;s stock closing at $118.44, the total value of the shares sold amounted to approximately $2.65 million. Palantir has been in the spotlight due to its recent defense contracts and <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45113101/palantir-stock-is-up-55-ytd-heading-into-earnings-next-week-whats-going-on">upcoming earnings report</a> on May 5. The company has been actively involved in the TITAN program, delivering systems to the U.S. Army, which has contributed to its stock&#8217;s 55% year-to-date increase. 
The AMD Trade
Ark Invest also increased its stake in Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) through ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) and ARKW. The firm purchased 106,769 shares in ARKK and 12,349 shares in ARKW, totaling a value of approximately $11.56 million, with AMD&#8217;s stock closing at $97.35. This move comes amid industry discussions about Huawei&#8217;s development of an AI chip, <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45052912/whats-going-on-with-advanced-micro-devices-stock-monday">potentially challenging competitors</a>. Despite this, AMD continues to be a key player in the semiconductor industry. Notably, Ark has made AMD purchases <a href="https://in.benzinga.com/25/04/45089384/cathie-wood-bets-against-mark-zuckerbergs-meta-ahead-of-crucial-earnings-report-loads-up-on-this-amazon-rival">throughout this week</a> so far. The company loaded up on $3.79 million worth of shares on Monday and another $747,923 worth on Tuesday.
The Shopify Trade
Ark Invest&#8217;s purchase of 12,632 shares of Shopify Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) through its ARKW ETF reflects a strategic investment in the e-commerce sector. With SHOP&#8217;s stock closing at $95.00, the transaction was valued at approximately $1.2 million. Shopify faces new challenges due to <a href="https://www.benzinga.com/markets/25/04/44640798/trump-ends-de-minimis-exemptions-shopify-bigcommerce-and-lightspeed-face-new-headwinds">changes in trade policies</a>, impacting e-commerce platforms. Despite these headwinds, Shopify remains a significant player in the digital commerce landscape. 
Other Key Trades:
<ul>
<li>CRISPR Therapeutics AG (CRSP) &#8211; Sold 354,188 shares in ARKK.</li>
<li>Pacific Biosciences of California Inc. (PACB) &#8211; Bought 345,607 shares in ARKK.</li>
<li>10X Genomics Inc. (TXG) &#8211; Bought 184,619 shares in ARKK.</li>
<li>Kratos Defense and Security Solutions Inc. (KTOS) &#8211; Sold 75,284 shares in ARKQ and 7,842 shares via ARKX.</li>
<li>Caterpillar Inc. (CAT) &#8211; Bought 6,933 shares in ARKQ.</li>
</ul>
Benzinga Edge Stock Rankings places Palantir Momentum in the 99th percentile and Growth in the 86th percentile. How do other potent rivals compare? Find out here.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="803" height="105" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30215237/Screenshot-2025-05-01-at-10.40.03.png" alt="" class="wp-image-896057" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30215237/Screenshot-2025-05-01-at-10.40.03.png 803w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30215237/Screenshot-2025-05-01-at-10.40.03-300x39.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30215237/Screenshot-2025-05-01-at-10.40.03-768x100.png 768w" sizes="(max-width: 803px) 100vw, 803px" /></figure>
Photo Courtesy: Ira Lichi on Shutterstock.com
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

Markets

ETFs

ARKK

ARKW

ARKX

CRSP

KTOS

PLTR

SHOP

Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant

Davos Alzheimer's Collaborative Announces PacBio Will Be A Technology Partner To Its North African Dementia Registry Project

Canaccord Genuity analyst Kyle Mikson maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Buy and maintains $3 price target.

Canaccord Genuity Maintains Buy on Pacific Biosciences, Maintains $3 Price Target

Pacific Biosciences of California Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) on Wednesday announced preliminary revenue of $36.9 million versus a <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $33.49 million</a>.
The company said the first quarter met expectations, despite impacts from ongoing uncertainty in NIH funding in the United States and broader economic headwinds <a href="https://www.benzinga.com/pressreleases/25/04/g44710496/pacbio-announces-preliminary-first-quarter-2025-revenue-and-reiterates-2025-revenue-guidance-of-15" target="_blank" rel="noreferrer noopener">affecting the industry</a>.
Vega system orders accelerated in the first quarter compared to the fourth quarter of 2024. The combination of system capability and its attractive price point enabled purchases from new and existing customers.
The sequencing solutions company said preliminary consumable revenue reached a company record. Annualized Revio pull-through per system was approximately $236,000. That&#8217;s in line with the company&#8217;s expectations in the low to mid $200,000s range.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44716951/enphase-rolls-out-scalable-grid-ready-iq-battery-5p-in-poland-with-15-year-warranty" rel="noreferrer noopener">Enphase Rolls Out Scalable, Grid-Ready IQ Battery 5P in Poland With 15-Year Warranty</a>
&#8220;&#8230;The Vega launch is progressing well, attracting more customers to HiFi sequencing and is expanding our addressable applications. While the funding and general macroeconomic environment is having an impact on our ability to place more instruments, particularly Revio systems at academic customers, we are encouraged by the consistent Revio utilization and annualized consumable pull-through, which remain in line with our expectations,&#8221; said Christian Henry, President and CEO of PacBio.
&#8220;We believe we are on pace to achieve the financial goals we set earlier this year. However, given the persistent uncertainty surrounding academic and NIH funding, along with the introduction of new tariffs, we are taking strategic steps to reduce spending and reinforce our plan to reach positive cash flow by the end of 2027.&#8221;
The company says it will focus on three key priorities:
<ul>
<li>Accelerating the adoption of HiFi sequencing,</li>
<li>Investing in initiatives that are targeted to improve gross margin.</li>
<li>Advancing innovation in long-read sequencing portfolio to enhance platform scalability and reduce costs.</li>
</ul>
PacBio is also restructuring commercial organization to streamline management and improve sales force efficiency.
Guidance: The company reiterates its previous 2025 revenue forecast of $155 million to $170 million versus the consensus of $161.51 million.
<ul>
<li>Growth in Vega shipments offset a year-over-year decline in Revio system shipments, with annualized pull-through per Revio system in the low to mid $200,000 range.</li>
<li>2025 non-GAAP gross margin to be between 35% and 40%.</li>
</ul>
In response to ongoing market uncertainty, PacBio is executing a plan to reduce headcount across all functions and non-headcount-related expenses to lower its annualized non-GAAP operating expense run-rate by $45 million to $50 million by year-end, compared to its prior guidance of $270 million to $280 million. Its ending cash and investments balance will also be higher than the previous guidance of approximately $260 million.
Price Action: PACB stock is up 8.75% at $1.31 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44715789/fda-approves-bristol-myers-opdivo-plus-yervoy-combo-for-untreated-colorectal-cancer-patients" target="_blank" rel="noreferrer noopener">FDA Approves Bristol Myers&#8217; Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients</a></li>
</ul>

Guidance

Health Care

Trading Ideas

Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs

Press Releases

PacBio Announces First Quarter 2025 Financial Results

Legal

PacBio Board Independent Investigation Concludes Allegations Unsubstantiated

PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

PacBio to Present at Upcoming Investor Conferences

Contracts

Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio

PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications

Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

BioLife Solutions

Bruker

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Pacific Biosciences

Intérêt court

Pacific Biosciences (NASDAQ:PACB) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL